METHODS	Sixty patients admitted for acute myocardial infarction were randomized to receive either simvastatin 40 mg ( SIMVA ) , a combination of simvastatin 40 mg and ezetimibe 10 mg ( EZE/SIMVA ) , or no lipid-lowering drugs ( NLLD ) and had their lipid levels assessed 2 , 4 and 7 days later .\